Recently, Handra-Luca et al. [66] reported that low ERCC1 protein expression was associated with higher rates of tumor response (79% versus 56%, P = .04) and lower risk of cancer-specific death (risk ratio 0.42, P = .04) in patients with SCCHN treated with cisplatin-based induction chemotherapy. This evidence concerns the gene ERCC1 and head and neck squamous cell carcinoma.